Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

2018631 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 19, Issue 9, pp. 1192-1204

Field-Weighted Citation Impact: 57.89